Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

BACKGROUND: Ad26.COV2.S is a well-tolerated and effective vaccine against COVID-19. We evaluated durability of anti-SARS-CoV-2 antibodies elicited by single-dose Ad26.COV2.S and the impact of boosting. METHODS: In randomized, double-blind, placebo-controlled, phase 1/2a and phase 2 trials, participa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadoff, Jerald, Le Gars, Mathieu, Brandenburg, Boerries, Cárdenas, Vicky, Shukarev, Georgi, Vaissiere, Nathalie, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne Marit, Jongeneelen, Mandy, Kaszas, Krisztian, Tolboom, Jeroen, Scheper, Gert, Hendriks, Jenny, Ruiz-Guiñazú, Javier, Struyf, Frank, Van Hoof, Johan, Douoguih, Macaya, Schuitemaker, Hanneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165876/
https://www.ncbi.nlm.nih.gov/pubmed/35667914
http://dx.doi.org/10.1016/j.vaccine.2022.05.047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165876/
https://www.ncbi.nlm.nih.gov/pubmed/35667914
http://dx.doi.org/10.1016/j.vaccine.2022.05.047

Ejemplares similares